Case Study
Improving Patient Safety With RFID-Enabled Packaging And Logistics
Click Here To Download:
•Case Study: Improving Patient Safety With RFID-Enabled Packaging And Logistics
By Impinj, Inc.
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. The company currently markets six proprietary products in the United States: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA™ (fentanyl buccal tablet) [C-II], ACTIQ® (oral transmucosal fentanyl citrate) [C-II], GABITRIL® (tiagabine hydrochloride), TRISENOX® (arsenic trioxide) injection, and VIVITROL® (naltrexone for extended-release injectable suspension).
Cephalon began evaluating RFID technology in 2004. The initial phase of the pilot program, which captured the movements of placebo product and prototype packaging in a distribution center, was completed in December 2005. Phase 2 of the pilot program, completed in July 2006, consisted of shipping tagged product to an RFID-enabled wholesaler. Cephalon is currently implementing phase 3 of the pilot program which tests RFID-tagged cases and pallets in a manufacturing environment.
Click Here To Download:•Case Study: Improving Patient Safety With RFID-Enabled Packaging And Logistics
